Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICON: FMT for Recurrent CDI in IBD
NCT03106844Phase 2Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Aug 2017
- Primary completion
- Apr 2020
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic fecal microbiota in Clostridium difficile infection (CDI), sponsored by Brigham and Women's Hospital. Started Aug 2017; status: completed.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT03106844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03106844.